Special Issue

Pathogenesis of Pancreatic Cancer

Message from the Guest Editor

Pancreatic ductal adenocarcinoma (PDAC) is still one of the most aggressive and lethal malignancy in Western countries. PDAC cells are characterised by a tendency to infiltrate into the endothelium basement membrane and neurons and to propagate speedily to distant organs through the lymphatic system, causing metastasis. At molecular level, it is known that the activation of oncogenes, such as KRAS and NOTCH, and the blocking of tumour suppressor genes like p16, p53, SMAD4 and PTEN, are involved in the initiation and advancement of this disease. In addition, various cell signalling pathways, such EGFR, Akt and NF-kB, have been found to be disrupted, contributing to PDAC evolution. Despite all these advances in the understanding of the molecular pathogenesis of PDAC. further insight in the knowledge of this disease and new efficacious therapeutic strategies are urgently required in order to improve the outcomes for PDAC patients. The keywords of this special issue include: pancreatic cancer; pancreatic ductal enocarcinoma; molecular pathogenesis; chemotherapy; metastasis; cancer biology

Guest Editor

Prof. Dr. Marco Falasca

Department of Medicine and Surgery, University of Parma, Via Volturno, 39, 43125 Parma, Italy

Deadline for manuscript submissions

closed (30 November 2018)



Diseases

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 3.7 Indexed in PubMed



mdpi.com/si/11754

Diseases Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 diseases@mdpi.com

mdpi.com/journal/diseases





Diseases

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 3.7 Indexed in PubMed





About the Journal

Message from the Editorial Board

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

Diseases is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, Diseases is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Editors-in-Chief

Prof. Dr. Maurizio Battino

Department of Odontostomatologic and Specialized Clinical Sciences, Sez-Biochimica, Faculty of Medicine, Università Politecnica delle Marche, Via Ranieri 65, 60100 Ancona, Italy

Prof. Dr. Omar Cauli

Frailty and Cognitive Impairment—FROG Research Group, University of Valencia, 46010 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.